Trials / Completed
CompletedNCT02063295
An Efficacy, Safety, and Pharmacokinetics Study of Beloranib in Obese Subjects With Hypothalamic Injury
Randomized, Double-Blind, Placebo Controlled, Phase 2a Trial of ZGN-440 (Subcutaneous Beloranib in Suspension), A Novel Methionine Aminopeptidase 2 Inhibitor, in Obese Subjects With Hypothalamic Injury to Evaluate Weight Reduction and Safety Over 4 Weeks Followed by an Optional 4-Week Open-Label Extension
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 14 (actual)
- Sponsor
- Zafgen, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics of beloranib in obese subjects with hypothalamic injury.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ZGN-440 sterile diluent | ZGN-440 sterile diluent/placebo |
| DRUG | ZGN-440 for injectable suspension |
Timeline
- Start date
- 2014-04-01
- Primary completion
- 2014-11-01
- Completion
- 2014-11-01
- First posted
- 2014-02-14
- Last updated
- 2016-07-18
Locations
4 sites across 2 countries: United States, Australia
Source: ClinicalTrials.gov record NCT02063295. Inclusion in this directory is not an endorsement.